Ionis Pharmaceuticals: Barclays cuts target price to $70 from $85
IONS•Barclays cut its target price for Ionis Pharmaceuticals to $70 from $85.
Related News
Altimmune's pemvidutide reduces liver fat in 48-week Phase 2b MASH trial
ALT•
Latch Inc Q3 revenue falls as hardware sales drop
LTCH•
Embraer signs long-term maintenance services deal with Mexicana
ERJ•
Koppers hosts investor meetings at Southwest IDEAS Investor Conference
KOP•
Twist Bioscience FY26 net loss widens 68% to $130.2 million; revenue rises 22% to $459.4 million
TWST•